Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
Sponsor: Rottapharm Biotech
Terminated
The good progress of the Italian national vaccination campaign against COVID-19 made impossible to complete the study as planned.
This PHASE1/PHASE2 trial investigates COVID-19 and COVID-19 Immunisation and is currently terminated or withdrawn. Rottapharm Biotech leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Nov 2022 — Apr 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rottapharm Biotech
- Takis
For direct contact, visit the study record on ClinicalTrials.gov .